文献速递白血病淋巴瘤

伊珠单抗奥唑米星治疗缓解期急性淋巴细胞白血病可测量残留病的2期研究

Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission.
PubMed 文献 · Blood · 2024-01-01

这项2期试验纳入26例首次或再次完全缓解且可测量残留病≥1×10⁻⁴的急性淋巴细胞白血病患者,接受伊珠单抗奥唑米星治疗,18例(69%)达到可测量残留病阴性,中位随访24个月时2年无复发生存率54%、总生存率60%,肝窦阻塞综合征见于2例(8%)。

要点

  • 伊珠单抗奥唑米星治疗可测量残留病阳性急性淋巴细胞白血病,18例(69%)达到可测量残留病阴性。
  • 中位随访24个月,全队列2年无复发生存率54%、2年总生存率60%。
  • 多数不良事件为低级别,肝窦阻塞综合征见于2例(8%)。

核心结论

  • 伊珠单抗奥唑米星治疗可测量残留病阳性的急性淋巴细胞白血病患者,可获得有利的生存、可测量残留病阴性率和安全性。

研究设计与样本

  • 2期试验纳入26例首次完全缓解(CR1)或再次及以上完全缓解(CR2+)且可测量残留病≥1×10⁻⁴的急性淋巴细胞白血病患者。
  • 伊珠单抗奥唑米星第1周期第1天0.6 mg/m²、第8天0.3 mg/m²,第2-6周期第1天和第8天0.3 mg/m²。
  • 中位年龄46岁(范围19-70岁),19例(73%)为CR1,7例(27%)为CR2+,16例(62%)为费城染色体阳性急性淋巴细胞白血病。

主要发现

  • 15例(58%)基线可测量残留病≥1×10⁻³。
  • 中位给药3个周期(范围1-6)。
  • 18例(69%)患者有应答并达到可测量残留病阴性。
  • 中位随访24个月(范围9-43个月),全队列2年无复发生存率54%,2年总生存率60%。

关键数值与推荐

  • 可测量残留病阳性定义为≥1×10⁻⁴。
  • 可测量残留病阴性率为69%(18/26)。
  • 2年无复发生存率54%,2年总生存率60%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The detection of measurable residual disease (MRD) is the strongest predictor of relapse in acute lymphoblastic leukemia (ALL). Using inotuzumab ozogamicin in the setting of MRD may improve outcomes. Patients with ALL in first complete remission (CR1) or beyond (CR2+) with MRD ≥ 1 × 10-4 were enrolled in this phase 2 trial. Inotuzumab was administered at 0.6 mg/m2 on day 1 and 0.3 mg/m2 on day 8 of cycle 1, then at 0.3 mg/m2 on days 1 and 8 of cycles 2-6. Twenty-six consecutive patients with a median age of 46 years (range, 19-70 years) were treated. Nineteen (73%) were in CR1 and seven (27%) in CR2+; 16 (62%) had Philadelphia chromosome-positive ALL. Fifteen (58%) had baseline MRD ≥ 1 × 10-3. A median of 3 cycles (range, 1-6) were administered. Eighteen (69%) patients responded and achieved MRD negativity. After a median follow-up of 24 months (range, 9-43), the 2-year relapse-free survival rate was 54% and the 2-year overall survival rate was 60% in the entire cohort. Most adverse events were low grade; sinusoidal obstruction syndrome was noted in 2 patients (8%). In summary, inotuzumab ozogamicin resulted in favorable survival, MRD negativity rates, and safety profiles for patients with ALL and MRD-positive status. This study was registered at www.ClinicalTrials.gov as #NCT03441061.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Jabbour E, Haddad FG, Short NJ, et al. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood. 2024. PMID: 37879077. doi:10.1182/blood.2023022330

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。